Abstract
The human lung carcinoma cell line DLKP was exposed to sequential pulses of 10 commonly used chemotherapeutic drugs (VP-16, vincristine, taxotere, mitoxantrone, 5-fluorouracil, methotrexate, CCNU, BCNU, cisplatin and chlorambucil); resulting cell lines exhibited resistance to the selecting agents (ranging approx. 1.5- to 36-fold) and, in some cases, cross-resistance to methotrexate (approx. 1.4- to 22-fold), vincristine (1.6- to 262-fold), doxorubicin (Adriamycin, approx. 1.1- to 33-fold) and taxotere (approx. 1.1- to 36-fold). Several of the variants displayed collateral sensitivity to cisplatin. A marked increase in in vitro invasiveness and motility was observed with variants pulsed with mitoxantrone, 5-fluorouracil, methotrexate, BCNU, cisplatin and chlorambucil. There was no significant change in invasiveness of cells pulsed with VP-16, vincristine, taxotere or CCNU. All of the pulse-selected variants showed elevated levels of MDR-1/P-gp protein by Western blot analysis, although mdr-1 mRNA levels were not increased (except for DLKP-taxotere). In DLKP-taxotere, MRP1 protein levels were also greatly elevated, but mrp1 mRNA levels remained unchanged. BCRP was upregulated in DLKP-mitoxantrone at both the mRNA and protein leve...Continue Reading
References
Aug 1, 1977·British Journal of Cancer·J V Moore, B Dixon
Apr 15, 1975·International Journal of Cancer. Journal International Du Cancer·L M van PuttenM Füzy
Apr 1, 1992·Cancer Genetics and Cytogenetics·E LawM Clynes
Mar 23, 1990·Science·B A TeicherE Frei
Nov 1, 1971·Radiology·S StefaniJ Abbate
Nov 1, 1984·Cancer·G J SlotmanB F Rush
Jun 7, 1994·Proceedings of the National Academy of Sciences of the United States of America·P A BaumanA E Cress
Sep 1, 1994·Journal of Cellular Biochemistry·R S KerbelC H Graham
Dec 1, 1996·Cancer Metastasis Reviews·M J HendrixR E Seftor
May 29, 1997·International Journal of Cancer. Journal International Du Cancer·M HeenanM Clynes
Apr 1, 1997·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·E MoranM Clynes
Nov 15, 1997·Cancer·E C WoodhouseL A Liotta
Jan 1, 1997·Advances in Experimental Medicine and Biology·Y A DeClerckW E Laug
Mar 5, 1998·Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine·S McBrideM Clynes
Oct 30, 1998·Critical Reviews in Oncology/hematology·M ClynesK Scanlon
Dec 22, 1998·Journal of Cancer Research and Clinical Oncology·M MitsumotoH Nakano
Dec 23, 1998·Proceedings of the National Academy of Sciences of the United States of America·L A DoyleD D Ross
Sep 4, 1999·Invasion & Metastasis·M SuzukiH Suzuki
Oct 6, 1999·American Journal of Respiratory and Critical Care Medicine·J Pérez-RamosA Pardo
Nov 24, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·M MichaelF A Shepherd
Jul 7, 2000·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Y A DeClerck
Aug 17, 2000·Journal of the National Cancer Institute·P BorstJ Wijnholds
Apr 18, 2001·Breast Cancer Research : BCR·J SchneiderA Alba
May 4, 2001·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Y LiangM Clynes
Jan 24, 2002·Journal of Bioenergetics and Biomembranes·Z E SaunaS V Ambudkar
Aug 22, 2002·Current Cancer Drug Targets·Y LiangMartin Clynes
Mar 26, 2003·Clinical & Experimental Metastasis·Garth L NicolsonAmr Moustafa
Citations
Jan 28, 2012·Journal of Huazhong University of Science and Technology. Medical Sciences = Hua Zhong Ke Ji Da Xue Xue Bao. Yi Xue Ying De Wen Ban = Huazhong Keji Daxue Xuebao. Yixue Yingdewen Ban·Ye RenJiang Wang
Mar 6, 2009·Anti-cancer Drugs·Susanna MiettinenTimo Ylikomi
Dec 22, 2006·BMC Cancer·Roman A BlahetaJindrich Cinatl
Feb 28, 2009·Annals of Surgical Oncology·Li LiChengzhi Xu
Sep 21, 2011·PloS One·Ling YaoLisa X Xu
Jun 14, 2013·PloS One·Henry OgbomoPeter A Forsyth
Feb 9, 2012·International Journal of Molecular Sciences·Miroslav BarancikAlbert Breier
Oct 27, 2015·International Journal of Molecular Sciences·Fei ZhangRuifang Niu
Apr 4, 2015·Expert Opinion on Drug Metabolism & Toxicology·Helena JoyceAnnemarie Larkin
Mar 26, 2011·Journal of Pharmacological Sciences·Yuko TakebaShinichi Kobayashi
Jun 27, 2013·PloS One·Birgit LohbergerNadine Kretschmer
Mar 19, 2014·PloS One·Hsiao-Chi TsaiChih-Hsin Tang
Sep 19, 2009·Trends in Pharmacological Sciences·Matthew D HallMichael M Gottesman
Feb 8, 2005·Biochemical and Biophysical Research Communications·Haidong XuCheol-Hee Choi
Aug 24, 2005·Immunopharmacology and Immunotoxicology·Farshid SaadatAbbas Mirshafiey
Sep 21, 2007·Cancer Treatment Reviews·Britta StordalRoss Davey
Apr 9, 2005·Cell Death and Differentiation·M V Blagosklonny
Sep 1, 2004·The Journal of Biological Chemistry·Alfonso CatalanoAntonio Procopio
Nov 12, 2016·Oncotarget·Cheng-Ying ShenMong-Hsun Tsai
May 19, 2009·International Journal of Cancer. Journal International Du Cancer·Ju Han SongTae Sung Kim
Mar 8, 2013·International Journal of Molecular Medicine·Yang LiZhi Wen Jiang
Jan 5, 2019·Journal of breast cancer·Chang-Chang Han, Fu-Sheng Wan
Jan 6, 2010·Critical Reviews in Oncology/hematology·David J Stewart